Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics and Merck Collaborate on Alzheimer s Studies

NEW YORK, July 28 (GenomeWeb News) - Celera Diagnostics said today that it has entered into an agreement with Merck to identify novel targets for drug discovery and diagnostic markers related to Alzheimer's disease.


Celera Diagnostics, a joint venture of Celera Genomics and Applied Biosystems, will conduct a functional genome scan to identify novel gene associations with Alzheimer's. Merck will receive rights for therapeutic applications, while Celera Diagnostics will retain the rights to diagnostic applications, Celera said.


Merck will also fund discovery research at Celera Diagnostics related to the project, and will make clinical milestone payments and pay a royalty on sales of potential commercial pharmaceutical products.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.